Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.64 USD | +3.10% | -4.66% | -32.55% |
Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.55% | 1.93B | |
+1.70% | 42.59B | |
+7.94% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+9.02% | 24.81B | |
-24.71% | 18.17B | |
+28.25% | 12.05B | |
-3.35% | 11.7B | |
+6.93% | 11.1B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Transcript : Intellia Therapeutics, Inc., Q2 2022 Earnings Call, Aug 04, 2022